2023年12月11日,美国糖尿病协会(American Diabetes Association,ADA)正式颁布了《2024年糖尿病诊疗标准(Standards of Care in Diabetes-2024)》.长期以来,ADA糖尿病诊疗标准一直被视为国际糖尿病领域的风向标,对于各国糖尿病诊疗有很大的参考价值.《2024年糖尿病诊疗标准》继续强调了"以降糖为中心"向"以患者为中心"诊疗模式的转变,突出强调了"合理控糖、管理体重、改善心肾预后"作为糖尿病患者综合管理的重要性,同时继续肯定了胰高血糖素样肽-1受体激动剂等新型降糖药物以及减重代谢手术在2型糖尿病综合管理方面的优势地位.
Abstract
On December 11,2023,the American Diabetes Association(ADA)promulgated the Standards of Care in Diabetes(2024).For a long time,the ADA promulgated the Standards of Care in Diabetes had been regarded as the international guide in the field of diabetes,which has a great reference value for the diagnosis and treatment of diabetes in various countries.The new standard continues to emphasize the transformation of the diagnosis and treatment model from the glucose reduction to the patients,highlighting the importance of reasonable control of glucose,weight management,and improvement of cardiac and renal prognosis as the comprehensive management of diabetes patients,meanwhile continues to affirm the advantages of new hypoglycemic drugs such as glucagon like peptide-1 receptor agonist and metabolic surgery in the comprehensive management of type 2 diabetes mellitus.
维普
万方数据